Cargando…
ZIKA-001: Safety and Immunogenicity of an Engineered DNA Vaccine Against ZIKA virus infection
BACKGROUND: While Zika virus (ZIKV) infection is typically self-limited, congenital birth defects and Guillain-Barré syndrome are well-described. There are no therapies or vaccines against ZIKV infection. METHODS: ZIKA-001 is a phase I, open label, clinical trial designed to evaluate the safety, sid...
Autores principales: | Tebas, Pablo, Roberts, Christine C, Muthumani, Kar, Reuschel, Emma, White, Scott, Khan, Amir S, Racine, Trina, Choi, Hyeree, Zaidi, Faraz, Boyer, Jean, Kudchodkar, Sagar, Park, Young K, Trottier, Sylvie, Remigio, Celine, Krieger, Diane, Kobinger, Gary P, Weiner, David, Maslow, Joel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631827/ http://dx.doi.org/10.1093/ofid/ofx163.693 |
Ejemplares similares
-
Rapid response to an emerging infectious disease – Lessons learned from development of a synthetic DNA vaccine targeting Zika virus
por: Kudchodkar, Sagar B., et al.
Publicado: (2018) -
Synthetic nucleic acid antibody prophylaxis confers rapid and durable protective immunity against Zika virus challenge
por: Choi, Hyeree, et al.
Publicado: (2019) -
Zika Virus Vaccines: Challenges and Perspectives
por: das Neves Almeida, Raquel, et al.
Publicado: (2018) -
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial
por: Modjarrad, Kayvon, et al.
Publicado: (2019) -
A novel synthetic DNA vaccine elicits protective immune responses against Powassan virus
por: Choi, Hyeree, et al.
Publicado: (2020)